Analysts Set Geron Co. (NASDAQ:GERN) PT at $7.25

Geron Co. (NASDAQ:GERN) has been given a consensus recommendation of “Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $6.91.

Several analysts have issued reports on the company. Needham & Company LLC upped their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. B. Riley cut their target price on Geron from $5.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday. Finally, Barclays raised Geron to a “strong-buy” rating in a research note on Friday, November 29th.

Geron Stock Down 3.4 %

Shares of NASDAQ GERN opened at $2.54 on Friday. Geron has a 12 month low of $1.64 and a 12 month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.94 and a beta of 0.53. The business has a 50-day moving average of $3.16 and a 200-day moving average of $3.89.

Institutional Trading of Geron

A number of institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in shares of Geron during the fourth quarter valued at approximately $45,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Geron by 24.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,267,176 shares of the biopharmaceutical company’s stock valued at $4,486,000 after acquiring an additional 246,433 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Geron by 64.6% during the fourth quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock valued at $41,019,000 after acquiring an additional 4,549,031 shares in the last quarter. Velan Capital Investment Management LP bought a new position in shares of Geron during the fourth quarter valued at approximately $173,000. Finally, Vestal Point Capital LP raised its holdings in shares of Geron by 947.6% during the fourth quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock valued at $38,940,000 after acquiring an additional 9,950,000 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.